In this study involving Chinese participants during the 20 years preceding clinical diagnosis of sporadic Alzheimer’s disease, we observed the time courses of CSF biomarkers, the times before diagnosis at which they diverged from the biomarkers from a matched group of participants who remained cognitively normal, and the temporal order in which the biomarkers became abnormal.

The internet is abuzz with claims that biomarker blood tests are the key to predicting dementia 15 years out. Here's what you need to know about what these tests can — and can't — do.

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau coalescing in the brain.

This guide provides information about blood tests for people with cognitive difficulties, such as problems with memory and/or thinking, which could be due to Alzheimer’s disease (AD). Testing for people with cognitive difficulties may be offered as part of a clinical evaluation or research study.

Dr. Ali Rezai told 60 Minutes that new developments in blood testing could help doctors identify patients who are at risk for Alzheimer's disease.

Newer blood tests can help doctors diagnose Alzheimer's disease without a brain scan or spinal tap. But some tests are more accurate than others.

Feel like your head is spinning? Like a little blood sample in a centrifuge, perhaps? No need to panic. It just means you are straining, like the rest of us, to keep up with the Alzheimer's disease plasma biomarker development field. New markers, new assays, new protocols seem to arrive at a dizzying pace.

Experts have raised concerns about Quest Diagnostics’ $399 consumer-initiated Alzheimer’s disease test, telling 360Dx that it is unclear whether the product is accurate enough to support its use

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would market a plasma Aβ42/ Aβ40 Alzheimer’s test to the public.

Herein, we review data on BBBMs that are closest to clinical implementation, particularly those based on measures of amyloid-β peptides and phosphorylated tau species. We discuss key parameters and considerations for the development and potential deployment of these BBBMs under different contexts of use and highlight challenges at the methodological, clinical, and regulatory levels.

CEOi held a BBM Workgroup meeting at AAIC 2023. Workstream leads, Suzanne Schindler, Michelle Mielke, and Chi Udeh-Momoh presented progress on the Workgroup’s outputs to prepare for widespread adoption of blood-based biomarkers into clinical practice

Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs.

Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both amyloid and tau pathology in clinical settings, but their performance in heterogeneous community-based populations is unclear. We examined P-tau181 and P-tau217 (n = 1,329, aged 30–98 years), in the population-based Mayo Clinic Study of Aging.